⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 19, 2014Science Translational MedicineOpen Access

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

View Full Paper

Ask AI

Bookmark

Share

Abstract

CD19 CAR T cell therapy induces complete remissions in 88% of 16 adult patients with relapsed or refractory acute lymphoblastic leukemia.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davila et al. (2014) studied this question.

synapsesocial.com/papers/68f8a73924b0bc2d85900680 https://doi.org/10.1126/scitranslmed.3008226

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaOriginal Research · 2013 · 2,100 citations
2Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: The memorial Sloan-Kettering-New York-II protocolRCT · 1993 · 104 citations
3C-reactive protein: a critical updateReview · 2003 · 3,524 citations
4POMP combination chemotherapy of adult acute leukemiaOriginal Research · 1973 · 85 citations
5Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia2013 · 3,539 citations